FARMINGTON, CT, LambdaVision, an innovative biotech company, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund.
LambdaVision, an innovative biotech company developing a protein-based artificial retina to help patients regain sight lost to retinal degenerative diseases, announced it secured the first closing of its seed round being led by Aurelia Foundry Fund, a fund spun out of MIT. The round also includes investment from Boryung, a publicly listed Korean pharmaceutical company, and E2MC Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
